Combination of brachytherapy and chemotherapy not superior to pelvic radiotherapy according to GOG-249
Letter to the Editor
- 124 Downloads
Compliance with ethical guidelines
Conflict of interest
A. Papachristofilou and T. Finazzi declare that they have no competing interests.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.de Boer SM et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19(3):295–309. https://doi.org/10.1016/S1470-2045(18)30079-2 CrossRefGoogle Scholar
- 3.Matei D et al (2017) A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. J Clin Oncol 35(15_suppl):5505. https://doi.org/10.1200/jco.2017.35.15_suppl.5505 CrossRefGoogle Scholar
- 4.Matulonis U et al (2018) Analysis of patient-reported outcomes (PROs) for GOG-258, a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel (Cis-RT+CP) vs. carboplatin and paclitaxel (CP) for optimally debulked, locally advanced endometrial carcinoma. J clin Oncol 36(15_suppl):5589. https://doi.org/10.1200/jco.2018.36.15_suppl.5589 CrossRefGoogle Scholar
- 5.Randall M et al (2017) A phase 3 trial of pelvic radiation therapy versus vaginal cuff Brachytherapy followed by Paclitaxel/Carboplatin chemotherapy in patients with high-risk, early-stage Endometrial cancer: a gynecology oncology group study. Int J Radiat Oncol Biol Phys 99(5):1313. https://doi.org/10.1016/j.ijrobp.2017.09.008 CrossRefGoogle Scholar
© Springer-Verlag GmbH Germany, part of Springer Nature 2019